Compare JPMorgan Chase & Co (JPM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Moderna, Inc. — how do they compare? JPMorgan Chase & Co trades at $365.57 (market cap $962.37B), while Moderna, Inc. trades at $63.62 (market cap $24.18B). The key difference: JPMorgan Chase & Co is far larger — about 39.8× Moderna, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| JPM | MRNA | |
|---|---|---|
Market Cap | $962.37B | $24.18B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $362.04 | $81.80 |
52-Week Low | $282.84 | $22.36 |
Dividend Yield | 1.66% | — |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $365.63, up 1.62% today, with a bullish technical outlook and strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to an estimated $194.9B in 2026. The stock shows robust profitability with a net income margin of 33.38% and ROE of 18.43%, supported by a moderate P/E of 15.51. Analyst consensus is a 'Moderate Buy' with a $374.18 price target, indicating potential upside amid positive sentiment.
JPM offers a solid investment case driven by earnings growth and sector leadership, but faces risks from macroeconomic volatility and geopolitical tensions. The stock's current price near resistance at $366 requires monitoring for breakout potential, while institutional accumulation and CEO insights on economic risks highlight both opportunity and caution for investors.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
